Consumption of meat containing ractopamine might enhance tumor growth through induction of asparagine synthetase
Frank S. Fan

There is currently no evidence of the carcinogenic effect of the β-adrenergic agonist ractopamine added in finishing swine and cattle feed for promoting leanness. Nonetheless, it has the capability of stimulating expression of asparagine synthetase (ASNS) through activating transcription factor 5, and many other genes involved in the stress reaction in the skeletal muscle of pigs according to published scientific articles. Because overexpression of ASNS has been detected as a key player in amino acid response and unfolded protein response during the development of not a few malignant diseases, especially those with KRAS mutations, and found to be closely related to tumor proliferation, invasion and metastasis, it seems reasonable to hypothesize that intake of ractopamine residue in meat might bring negative effects to cancer patients. European Journal of Cancer Prevention 31: 82–84 Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc.

Keywords: amino acid response, asparagine synthetase, feed additive, ractopamine

Department of Medicine, Section of Haematology and Oncology, Ministry of Health and Welfare Taitung Hospital, Taitung County, Taiwan

Correspondence to Frank S. Fan, MD, PhD, Department of Medicine, Ministry of Health and Welfare Taitung Hospital, No. 1, Wuquan Street, Taitung City, Taitung County 950, Taiwan
Tel: +886 89 324112, ext 1500; fax: +886 89 323891; e-mail: fantast.fan@msa.hinet.net

Received 22 November 2020 Accepted 30 November 2020

Introduction
Ractopamine, classified as a β-adrenergic agonist, has been used to increase carcass lean percentage and growth rate by pork and beef producers in the USA in the past two decades. Although its use has obtained approval as a feed additive for swine in the USA, Canada, Mexico and Brazil, ractopamine is prohibited in the European Union, China and many other countries (Vezzoni de Almeida et al., 2012). Despite the potential contribution of ractopamine to environmental protection by increasing efficiency of husbandry, shortening finishing swine growth period, decreasing feed need and thus reducing the amount of water, fertilizer and pesticide for crop cultivation (Woods et al., 2011), people inevitably are still worried about the safety of ractopamine residue in meat especially in those countries where pork is imported from the USA.

In addition to the health risk of cardiovascular functional disorders and cardiovascular diseases which might lead to life expectancy decrease (Zaitseva et al., 2014), another major concern is whether ractopamine will promote malignancy formation. Even with the promise that genotoxicity and carcinogenicity could be excluded with acceptable daily intakes on recommended maximal residue limits of ractopamine in animal feed except for a dose-dependent slightly increased incidence of uterine leiomyoma in rat studies (Joint FAO/WHO Expert Committee on Food Additives 2004; Scientific Opinion of the Panel on Additives and Products or Substances used in Animal Feed 2009), what’s the effect of ractopamine on cancer already existing remains a question to be carefully investigated. Herein, a hypothesis is raised that ractopamine might stimulate tumor growth through induction of asparagine synthetase (ASNS) expression.

Metabolic reprogramming in cancer cells
During tumorigenesis and metastasis, being affected by oncogene activation and tumor suppressor inactivation, cancer cells rewire their metabolism to meet the biosynthetic demands of high proliferation rates and achieve a new state of homeostasis, losing expression of some amino-bolic genes and becoming eagerly dependent on certain specific amino acids which could be deprived by enzymes designed as therapeutic modalities (Maggi and Scotti, 2019; Garcia-Bermudez et al., 2020). Nevertheless, cancer cells could also manage to start initially silent genes in response to the urgency of producing amino acids they need. It has been disclosed that one of these genes activated in cell stress is ASNS.

Asparagine synthetase in tumor biology
ASNS produces asparagine from aspartate in an ATP-dependent process during which glutamine is converted to glutamate at the same time (Lomelino et al., 2017). The basal expression of ASNS is generally low in mammalian organs except in the pancreas and testes as shown in rat experiments and human studies. Nonetheless, transcription of the gene for ASNS could be turned on under stress conditions, such as amino acid response and...
Ractopamine might enhance tumor growth

Fan

Ractopamine increases asparagine synthetase in skeletal muscles

In a recently published study, skeletal muscle transcriptome analysis in pigs administered with ractopamine (20 ppm in feed) disclosed remarkably increased gene expressions of ASNS and activating transcription factor 5 (ATF5) but not ATF4 in comparison with pigs injected with growth hormone Reporcin and pigs on ordinary feed (Brown et al., 2018). On the other hand, the expression of over 20 ATF4 target genes was induced by ractopamine. The authors concluded that ractopamine treatment resulted in an integrated stress response, peculiarly genes linked to amino acid biosynthesis and protein translation, in the skeletal muscle of pigs.

Hypothesis

Based on its nature as a \(\beta\)-adrenergic agonist, ractopamine surely acts on organs other than skeletal muscle as well. For patients who have malignant diseases including at least hepatocellular carcinoma, breast cancer, soft-tissue sarcoma, colon cancer and nonsmall cell lung cancer, particularly \(KRAS\)-mutated as mentioned above, consumption of meat containing ractopamine presumably will trigger expression of ASNS and other genes involved in integrated stress response and facilitate tumor growth or metastasis. The induction of ATF5 in the skeletal muscle of pigs provides an alternative pathway of stress response in addition to the well-known ATF4 one. Confirmation of this speculation awaits delicate laboratory investigation, clinical trials and long-term epidemiologic observation but the risk should not be ignored.

Discussion and conclusion

Depivation of asparagine with bacterial l-asparaginase has been adopted for the treatment of acute lymphoblastic leukemia (ALL) for four decades, taking advantage of the lack of ASNS expression in most ALL. Extension of l-asparaginase use to other malignancies has always been an attractive idea to clinicians as well. However, the main concern would be the correlation of l-asparaginase sensitivity with cellular ASNS content as seen in the studies of ALL, ovarian cancer and NK/T cell lymphoma (Su et al., 2008; Lorentzi and Weinstein 2009; Li et al., 2014). If ractopamine does stimulate ASNS expression, the strategy of l-asparaginase would be badly hindered in cancer patients who used to consume meat containing ractopamine. Finally, recent research discovered that besides its canonical role of protein synthesis, asparagine may have additional functions in the regulation of cellular growth, prompting reconsideration of the importance of ASNS in cancer therapy (Chiu et al., 2020). Accordingly, the presumed negative effects of ractopamine on cancer progression probably will soon become a novel focus of oncology research in the near future.

Acknowledgements

Conflicts of interest

There are no conflicts of interest.

References

Balasubramanian MN, Butterworth EA, Kilberg MS (2013). Asparagine synthetase: regulation by cell stress and involvement in tumor biology. Am J Physiol Endocrinol Metab 304:E789–E799.

Brown D, Ryan K, Daniel Z, Mareko M, Talbot R, Moreton J, et al. (2018). The \(\beta\)-adrenergic agonist, Ractopamine, increases skeletal muscle expression of asparagine synthetase as part of an integrated stress response gene program [published correction appears in Sci Rep 2019;9:15412]. Sci Rep 8:15915.

Chiu M, Taurino G, Bianchi MG, Kilberg MS, Bussolati O (2020). Asparagine synthetase in cancer: beyond acute lymphoblastic leukemia. Front Oncol 9:1480.

Garcia-Bermudez J, Williams RT, Guarecuco R, Birsoy K (2020). Targeting extracellular nutrient dependencies of cancer cells. Mol Metab 33:67–82.

Gwinn DM, Lee AG, Briones-Martín-Del-Campo M, Conn CS, Simpson DR, Scott Al, et al. (2018). Oncogenic \(KRAS\) regulates amino acid homeostasis and asparagine biosynthesis via ATF4 and Alters Sensitivity to L-Asparaginase. Cancer Cell 33:91–107.e6.

Hettmer S, Schinzel AC, Thessalova D, Schneider M, Parker CL, Bronson RT, et al. (2015). Functional genomic screening reveals asparagine dependence as a metabolic vulnerability in sarcoma. eLife 4:e09436.

Joint FAO/WHO Expert Committee on Food Additives (2004: Rome, Italy), World Health Organization & Food and Agriculture Organization of the United Nations (2004). Evaluation of certain veterinary drug residues in food: sixty-second report of the Joint FAO/WHO Expert Committee on Food Additives, World Health Organization. https://apps.who.int/iris/handle/10665/40309. [Accessed 12 December 2020]

Knott SR, Wagenblast E, Khan S, Kim SY, Soto M, Wagner M, et al. (2018). Asparagine bioavailability governs metastasis in a model of breast cancer [published correction appears in Nature 2018;556:139]. Nature 554:378–381.

Li Y, Zhang, X Hu T, Han L, Li R, Wen J, Zhang M (2014). Asparagine synthetase expression and its potential prognostic value in patients with NK/T cell lymphoma. Oncol Rep 32:853–859.

Lomelino CL, Andring JT, McKenna R, Kilberg MS (2017). Asparagine synthetase: function, structure, and role in disease. J Biol Chem 292:19952–19958.

Lorentzi PL, Weinstein JN (2009). Asparagine synthetase: a new potential biomarker in ovarian cancer. Drug News Perspect 22:61–64.

Maggini M, Scotti C (2019). Enzymes in metabolic anticancer therapy. In: Labrou N, editors. Therapeutic Enzymes: Function and Clinical Implications. Advances in Experimental Medicine and Biology. Vol 1148. Singapore: Springer, pp. 173–199.
Scientific Opinion of the Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) on a request from the European Commission on the safety evaluation of ractopamine (2009). Safety evaluation of ractopamine, EFSA J 1041:1–52.

Su N, Pan YX, Zhou M, Harvey RC, Hunger SP, Kilberg MS (2008). Correlation between asparaginase sensitivity and asparagine synthetase protein content, but not mRNA, in acute lymphoblastic leukemia cell lines. Pediatr Blood Cancer 50:274–279.

Toda K, Kawada K, Iwamoto M, Inamoto S, Sasazuki T, Shirasawa S, et al. (2016). Metabolic alterations caused by KRAS mutations in colorectal cancer contribute to cell adaptation to glutamine depletion by upregulation of asparagine synthetase. Neoplasia 18:654–665.

Vezzoni de Almeida V, Costa-Nunes AJ, Miyada VS (2012). Ractopamine as a metabolic modifier feed additive for finishing pigs: a review. Braz Arch Biol Technol 55:445–456.

Woods AL, Armstrong TA, Anderson DB, Elam TE, Sutton AL (2011). Case study: environmental benefits in United States finisher swine. Prof Anim Sci 27:492–499.

Zaitseva NV, Shur PZ, Atiskova NG, Kryyanov DA, Kamaldinov MR (2014). Health risk assessment of exposure to ractopamine through consumption of meat products. Int J Adv Res 2:538–545.

Zhang B, Dong LW, Tan YX, Zhang J, Pan YF, Yang C, et al. (2013). Asparagine synthetase is an independent predictor of surgical survival and a potential therapeutic target in hepatocellular carcinoma. Br J Cancer 109:14–23.